keyword
MENU ▼
Read by QxMD icon Read
search

circulating free DNA

keyword
https://www.readbyqxmd.com/read/29449275/circulating-tumor-dna-reveals-genetics-clonal-evolution-and-residual-disease-in-classical-hodgkin-lymphoma
#1
Valeria Spina, Alessio Bruscaggin, Annarosa Cuccaro, Maurizio Martini, Martina Di Trani, Gabriela Forestieri, Martina Manzoni, Adalgisa Condoluci, Alberto Arribas, Lodovico Terzi-Di-Bergamo, Silvia Laura Locatelli, Elisa Cupelli, Luca Ceriani, Alden A Moccia, Anastasios Stathis, Luca Nassi, Clara Deambrogi, Fary Diop, Francesca Guidetti, Alessandra Cocomazzi, Salvatore Annunziata, Vittoria Rufini, Alessandro Giordano, Antonino Neri, Renzo Boldorini, Bernhard Gerber, Francesco Bertoni, Michele Ghielmini, Georg Stüssi, Armando Santoro, Franco Cavalli, Emanuele Zucca, Luigi Maria Larocca, Gianluca Gaidano, Stefan Hohaus, Carmelo Carlo-Stella, Davide Rossi
The rarity of neoplastic cells in the biopsy imposes major technical hurdles that have so far limited genomic studies in classical Hodgkin lymphoma (cHL). By using a highly sensitive and robust deep-next-generation-sequencing approach for circulating tumor DNA (ctDNA), here we aimed at tracking the genetics of cHL in different clinical phases, and its modifications upon treatment. The analysis was based on specimens collected from 80 newly diagnosed and 32 refractory cHL patients, including longitudinal samples collected under ABVD chemotherapy and longitudinal samples from relapsing patients treated with chemotherapy and immunotherapy...
February 15, 2018: Blood
https://www.readbyqxmd.com/read/29441349/liquid-biopsy-in-clinical-management-of-breast-lung-and-colorectal-cancer
#2
REVIEW
Ivana Bratić Hench, Jürgen Hench, Markus Tolnay
Examination of tumor molecular characteristics by liquid biopsy is likely to greatly influence personalized cancer patient management. Analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and tumor-derived exosomes, all collectively referred to as "liquid biopsies," are not only a modality to monitor treatment efficacy, disease progression, and emerging therapy resistance mechanisms, but they also assess tumor heterogeneity and evolution in real time. We review the literature concerning the examination of ctDNA and CTC in a diagnostic setting, evaluating their prognostic, predictive, and monitoring capabilities...
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/29436707/the-molecular-pathology-of-cancer-from-pan-genomics-to-post-genomics
#3
REVIEW
David G Huntsman, Marc Ladanyi
As the cancer genomics of most major cancer types have been comprehensively catalogued over the past decade through a variety of national and international efforts, the delineation of cancer subtypes has been refined, and our understanding of critical cancer drivers and of the potentially targetable vulnerabilities they create has grown tremendously. The 2018 Annual Review Issue of The Journal of Pathology provides in-depth assessments of how these pan-genomic approaches have enabled advances in cancer classification, targeted therapy selection, and assessment of cancer progression, all of which are now genomically informed, using several cancer types as examples...
February 13, 2018: Journal of Pathology
https://www.readbyqxmd.com/read/29434880/clinical-significance-of-brafv600e-mutation-in-circulating-tumor-dna-in-chinese-patients-with-melanoma
#4
Huan Tang, Yan Kong, Lu Si, Chuanliang Cui, Xinan Sheng, Zhihong Chi, Jie Dai, Sifan Yu, Meng Ma, Xiaowen Wu, Jiayi Yu, Tianxiao Xu, Huan Yu, Junya Yan, Jun Guo
The present study aimed to assess the B rapidly accelerated fibrosarcoma (BRAFV600E) status in plasma from Chinese patients with melanoma, and evaluated its prognostic value following treatment with BRAF inhibitors. Mutation-specific 3D digital polymerase chain reaction (dPCR) was used to quantify BRAFV600E in circulating tumor DNA (ctDNA) in 58 patients with melanoma, prior to treatment with BRAF inhibitors. Correlations between baseline ctDNA levels and clinicopathological characteristics and clinical benefits were then statistically analyzed...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29431693/an-antigen-free-plasmacytoid-dendritic-cell-targeting-immunotherapy-to-bolster-memory-cd8-t-cells-in-nonhuman-primates
#5
Yuji Masuta, Takuya Yamamoto, Yayoi Natsume-Kitatani, Tomohiro Kanuma, Eiko Moriishi, Kouji Kobiyama, Kenji Mizuguchi, Yasuhiro Yasutomi, Ken J Ishii
The priming, boosting, and restoration of memory cytotoxic CD8+ T lymphocytes by vaccination or immunotherapy in vivo is an area of active research. Particularly, nucleic acid-based compounds have attracted attention due to their ability to elicit strong Ag-specific CTL responses as a vaccine adjuvant. Nucleic acid-based compounds have been shown to act as anticancer monotherapeutic agents even without coadministration of cancer Ag(s); however, so far they have lacked efficacy in clinical trials. We recently developed a second-generation TLR9 agonist, a humanized CpG DNA (K3) complexed with schizophyllan (SPG), K3-SPG, a nonagonistic Dectin-1 ligand...
February 5, 2018: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/29423116/a-plasma-telomeric-cell-free-dna-level-in-unaffected-women-with-brca1-or-and-brca2-mutations-a-pilot-study
#6
Shatovisha Dey, Natascia Marino, Kanokwan Bishop, Paige N Dahlgren, Aditi Shendre, Anna Maria Storniolo, Chunyan He, Hiromi Tanaka
Plasma cell-free DNA (cfDNA) is a small DNA fragment circulating in the bloodstream originating from both non-tumor- and tumor-derived cells. A previous study showed that a plasma telomeric cfDNA level decreases in sporadic breast cancer patients compared to controls. Tumor suppressor gene products including BRCA1 and BRCA2 (BRCA1&2) play an important role in telomere maintenance. In this study, we hypothesized that the plasma telomeric cfDNA level is associated with the mutation status of BRCA1&2 genes. To test this hypothesis, we performed plasma telomeric cfDNA quantitative PCR (qPCR)-based assays to compare 28 women carriers of the BRCA1&2 mutation with age-matched controls of 28 healthy women...
January 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29423090/efficacy-of-assessing-circulating-cell-free-dna-using-a-simple-fluorescence-assay-in-patients-with-triple-negative-breast-cancer-receiving-neoadjuvant-chemotherapy-a-prospective-observational-study
#7
Kwonoh Park, Miyoung Woo, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Jin Roh, Gyungyub Gong, Sung-Bae Kim
This study aims to assess cell-free DNA (CFD) by a fluorescence assay as a biomarker for early prediction of a pathologic complete response (pCR) and relapse in patients with triple-negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy. Patients with clinical stage II or III TNBC scheduled for neoadjuvant chemotherapy were prospectively enrolled. All patients underwent four cycles of Adriamycin plus cyclophosphamide (AC), followed by four cycles of cisplatin or docetaxel chemotherapy and surgery...
January 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29420226/serial-circulating-tumour-dna-analysis-during-multimodality-treatment-of-locally-advanced-rectal-cancer-a-prospective-biomarker-study
#8
Jeanne Tie, Joshua D Cohen, Yuxuan Wang, Lu Li, Michael Christie, Koen Simons, Hany Elsaleh, Suzanne Kosmider, Rachel Wong, Desmond Yip, Margaret Lee, Ben Tran, David Rangiah, Matthew Burge, David Goldstein, Madhu Singh, Iain Skinner, Ian Faragher, Matthew Croxford, Carolyn Bampton, Andrew Haydon, Ian T Jones, Christos S Karapetis, Timothy Price, Mary J Schaefer, Jeanne Ptak, Lisa Dobbyn, Natallie Silliman, Isaac Kinde, Cristian Tomasetti, Nickolas Papadopoulos, Kenneth Kinzler, Bert Volgestein, Peter Gibbs
OBJECTIVE: For patients with locally advanced rectal cancer (LARC), adjuvant chemotherapy selection following surgery remains a major clinical dilemma. Here, we investigated the ability of circulating tumour DNA (ctDNA) to improve risk stratification in patients with LARC. DESIGN: We enrolled patients with LARC (T3/T4 and/or N+) planned for neoadjuvant chemoradiotherapy. Plasma samples were collected pretreatment, postchemoradiotherapy and 4-10 weeks after surgery...
February 2, 2018: Gut
https://www.readbyqxmd.com/read/29419861/-data-analysis-of-non-invasive-prenatal-testing-based-on-special-loci-in-cell-free-fetal-dna
#9
Liming Xuan, Lingyin Kong, Yingying Xia, Yan Mao, Jingjing Shen, Yijun Zhu, Yongfeng Xue, Danfeng Sun, Huimin Liu, Bo Liang
OBJECTIVE To analyze the data of non-invasive prenatal testing based on specific loci of circulating cell-free fetal DNA (cffDNA). METHODS Selected loci of target chromosomes were analyzed by sequence capture and sequencing. Meanwhile, 600 loci were selected from other chromosomes for determining the concentration of cffDNA. RESULTS A total of 768 specific loci were captured on chromosomes 21 and 18, and used to determine whether the two were abnormal. When the minimum concentration of detected cffDNA was set at 3% and the threshold of Z score was set to [-6,6], the specificity of the analysis was 99...
February 10, 2018: Zhonghua Yi Xue Yi Chuan Xue za Zhi, Zhonghua Yixue Yichuanxue Zazhi, Chinese Journal of Medical Genetics
https://www.readbyqxmd.com/read/29419698/next-generation-sequencing-diagnostics-of-bacteremia-in-sepsis-next-genesis-trial-study-protocol-of-a-prospective-observational-noninterventional-multicenter-clinical-trial
#10
Thorsten Brenner, Sebastian O Decker, Silke Grumaz, Philip Stevens, Thomas Bruckner, Thomas Schmoch, Mathias W Pletz, Hendrik Bracht, Stefan Hofer, Gernot Marx, Markus A Weigand, Kai Sohn
BACKGROUND: Sepsis remains a major challenge, even in modern intensive care medicine. The identification of the causative pathogen is crucial for an early optimization of the antimicrobial treatment regime. In this context, culture-based diagnostic procedures (e.g., blood cultures) represent the standard of care, although they are associated with relevant limitations. Accordingly, culture-independent molecular diagnostic procedures might be of help for the identification of the causative pathogen in infected patients...
February 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29416824/the-dawn-of-the-liquid-biopsy-in-the-fight-against-cancer
#11
REVIEW
Irma G Domínguez-Vigil, Ana K Moreno-Martínez, Julia Y Wang, Michael H A Roehrl, Hugo A Barrera-Saldaña
Cancer is a molecular disease associated with alterations in the genome, which, thanks to the highly improved sensitivity of mutation detection techniques, can be identified in cell-free DNA (cfDNA) circulating in blood, a method also called liquid biopsy. This is a non-invasive alternative to surgical biopsy and has the potential of revealing the molecular signature of tumors to aid in the individualization of treatments. In this review, we focus on cfDNA analysis, its advantages, and clinical applications employing genomic tools (NGS and dPCR) particularly in the field of oncology, and highlight its valuable contributions to early detection, prognosis, and prediction of treatment response...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29416754/targeted-deep-sequencing-of-circulating-tumor-dna-in-metastatic-pancreatic-cancer
#12
Andreas W Berger, Daniel Schwerdel, Thomas J Ettrich, Alexander Hann, Stefan A Schmidt, Alexander Kleger, Ralf Marienfeld, Thomas Seufferlein
Purpose: Precision medicine in pancreatic ductal adenocarcinoma (PDAC) could be substantially supported by tools that allow to establish and monitor the molecular setup of the tumor. In particular, noninvasive approaches are desirable, but not validated. Characterization of circulating tumor DNA (ctDNA) may help to achieve this goal. Experimental Design: Blood samples from patients with metastatic PDAC prior to and during palliative treatment were collected. ctDNA and corresponding tumor tissue were analyzed by targeted next generation sequencing and droplet digital PCR for the 7 most frequently mutated genes in PDAC (TP53, SMAD4, CDKN2A, KRAS, APC, ATM, and FBXW7)...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29416630/prognostic-value-of-quantitative-ctdna-levels-in-non-small-cell-lung-cancer-patients
#13
Mariano Provencio, María Torrente, Virginia Calvo, David Pérez-Callejo, Lourdes Gutiérrez, Fernando Franco, Clara Pérez-Barrios, Miguel Barquín, Ana Royuela, Francisco García-García, Coralia Bueno, Aranzazu Garcia-Grande, Carlos Camps, Bartomeu Massuti, Eduardo Sotomayor, Atocha Romero
Background: Circulating tumor DNA (ctDNA) levels correlate well with tumor bulk. In this paper we aim to estimate the prognostic value of the dynamic quantification of ctDNA levels. Materials and Methods: A total of 251 serial plasma samples from 41 non-small-cell lung cancer patients who carried an activating EGFR mutation were analysed by digital PCR. For survival analysis, ctDNA levels were computed as a time-dependent covariate. Results: Dynamic ctDNA measurements had prognostic significance (hazard ratio for overall survival and progression free survival according to p...
January 2, 2018: Oncotarget
https://www.readbyqxmd.com/read/29409465/association-of-rs2282679-a-c-polymorphism-in-vitamin-d-binding-protein-gene-with-colorectal-cancer-risk-and-survival-effect-modification-by-dietary-vitamin-d-intake
#14
Yun Zhu, Peizhong Peter Wang, Guangju Zhai, Bharati Bapat, Sevtap Savas, Jennifer R Woodrow, Peter T Campbell, Yuming Li, Ning Yang, Xin Zhou, Elizabeth Dicks, John R Mclaughlin, Patrick S Parfrey
BACKGROUND: The rs2282679 A>C polymorphism in the vitamin D binding protein gene is associated with lower circulating levels of vitamin D. We investigated associations of this SNP with colorectal cancer (CRC) risk and survival and whether the associations vary by dietary vitamin D intake and tumor molecular phenotype. METHODS: A population-based case-control study identified 637 incident CRC cases (including 489 participants with follow-up data on mortality end-points) and 489 matched controls...
February 6, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29405770/liquid-biopsy-and-its-role-in-an-advanced-clinical-trial-for-lung-cancer
#15
Donald J Johann, Mathew Steliga, Ik J Shin, Donghoon Yoon, Konstantinos Arnaoutakis, Laura Hutchins, Meeiyueh Liu, Jason Liem, Karl Walker, Andy Pereira, Mary Yang, Susanne K Jeffus, Erich Peterson, Joshua Xu
Liquid biopsy methodologies, for the purpose of plasma genotyping of cell-free DNA (cfDNA) of solid tumors, are a new class of novel molecular assays. Such assays are rapidly entering the clinical sphere of research-based monitoring in translational oncology, especially for thoracic malignancies. Potential applications for these blood-based cfDNA assays include: (i) initial diagnosis, (ii) response to therapy and follow-up, (iii) tumor evolution, and (iv) minimal residual disease evaluation. Precision medicine will benefit from cutting-edge molecular diagnostics, especially regarding treatment decisions in the adjuvant setting, where avoiding over-treatment and unnecessary toxicity are paramount...
February 2018: Experimental Biology and Medicine
https://www.readbyqxmd.com/read/29401471/clinical-value-of-alu-concentration-and-integrity-index-for-the-early-diagnosis-of-ovarian-cancer-a-retrospective-cohort-trial
#16
Rong Zhang, Wangyang Pu, Shuyun Zhang, Li Chen, Weipei Zhu, Li Xiao, Chungen Xing, Kai Li
CA125 amounts have a large overlap in ovarian cancer and benign diseases. We conducted a retrospective cohort trial to assess the clinical value of circulating cell-free DNA concentration and integrity index for the diagnosis of ovarian cancer. A total of 150 patients were recruited. Plasma samples of 24 ovarian cancer patients, 12 benign ovarian cysts, and 12 healthy controls were assessed. By amplifying short ALU-115 repeat and long ALU-219 fragments, circulating cell-free DNA concentrations and integrity index were measured...
2018: PloS One
https://www.readbyqxmd.com/read/29401228/circulating-cell-free-dna-as-predictor-of-treatment-failure-after-neoadjuvant-chemo-radiotherapy-before-surgery-in-patients-with-locally-advanced-rectal-cancer-is-it-ready-for-primetime
#17
A Vivancos, E Élez, R Salazar
No abstract text is available yet for this article.
February 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29401004/molecular-testing-guideline-for-the-selection-of-patients-with-lung-cancer-for-treatment-with-targeted-tyrosine-kinase-inhibitors-american-society-of-clinical-oncology-endorsement-of-the-college-of-american-pathologists-international-association-for-the-study
#18
Gregory P Kalemkerian, Navneet Narula, Erin B Kennedy, William A Biermann, Jessica Donington, Natasha B Leighl, Madelyn Lew, James Pantelas, Suresh S Ramalingam, Martin Reck, Anjali Saqi, Michael Simoff, Navneet Singh, Baskaran Sundaram
Purpose In response to advances in the field, the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) recently updated their recommendations for molecular testing for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations...
February 5, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29400102/-in-vivo-analysis-of-circulating-cell-free-dna-release-and-degradation
#19
Barbara Kinga Barták, Zsófia Brigitta Nagy, Sándor Spisák, Zsolt Tulassay, Magdolna Dank, Péter Igaz, Béla Molnár
INTRODUCTION: Cell-free DNA (cfDNA) was first detected in human plasma in the 1940s, but the knowledge on its regulation and rate of release is incomplete. CfDNA can originate from both normal and tumour cells. AIM: Our aims were to investigate the rate of cfDNA's release in SHO mice/HT-29 colorectal adenocarcinoma cell line xenograft model and to define the decay of methylated and non-methylated DNA fragments in C57BL/6 bloodstream. METHOD: SHO mice were xenografted with human HT-29 cells, than blood samples were collected over 2 months...
February 2018: Orvosi Hetilap
https://www.readbyqxmd.com/read/29399517/neutrophil-extracellular-traps-are-increased-in-cancer-patients-but-does-not-associate-with-venous-thrombosis
#20
Rahmi Oklu, Rahul A Sheth, Keith H K Wong, Amin H Jahromi, Hassan Albadawi
Background: A single center, prospective tissue-based study was conducted to investigate an association between neutrophil extracellular traps (NETs) and venous thromboembolic disease in patients with malignancy. Methods: Plasma was collected from 65 patients in which 27 were cancer patients and 38 were age-matched non-cancer patients. Plasma NETs, circulating free DNA (cfDNA), DNase-1, endonuclease-G, endonuclease activity and thrombin-antithrombin III (TAT) complex levels was quantified...
December 2017: Cardiovascular Diagnosis and Therapy
keyword
keyword
85331
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"